Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

Content from other channels on our network

Neuroscientists propose clinical definition for brain fog in menopause

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

Community food network closes its soft plastics recycling loop

Real-time monitoring reduces risk at pumping station

Victorian oil refinery fire may impact fuel supply

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%

Six on the shelf: on-the-go protein, ready-to-cook veggies and more

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery

NZ Winegrowers calls for a White Wine Emoji

Nutrition claims compliance, fresh produce guide updated